Agenus | AGEN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Celldex Therapeutics USD 87.27M 511.09M 2025-12
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 5.62B 4.5B 2026-03
Intrexon USD 61.56M 26.1M 2024-06
J&J USD 17.44B 1.53B 2026-03
Jiangsu Hengrui CNY 5.52B 604.29M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck EUR 4.78B 669M 2025-12
Merck USD 18.17B 8.01B 2026-03
Northwest Biotherapeutics USD -108.65M 8.26M 2025-09
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 116M 7.24M 2025-12